Salt Lake City April 8 2009 -- Myriad Pharmaceuticals Inc. announced today that the FDA has approved an Investigational New Drug (IND) application to begin a Phase 1 clinical study with its Hsp90 inhibitor MPC-3100 for the treatment of cancer. The clinical development plan for MPC-3100 is designed to expedite the drug candidate through the clinical development path. The Phase 1 trial will assess the safety and pharmacokinetics profile of MPC-3100.

Influenza or Flu is a seasonal disease which outbreaks in various countries including United States.  This flu epidemic mostly emerges during winter season. It can affect all age groups but is usually most severe in the very old and very young. In the United States alone an estimated 36 000 people die each year from influenza and accompanying opportunistic infections and complications.